Causes & What We Know/August 8, 2026/3 min read

Understanding HLA and Type 1 Diabetes Risk: What a New Genetic Study Reveals

A large genetic study examined seven different conditions—including Type 1 diabetes—to understand what raises the risk of a rare bile duct cancer. Here's what researchers found about the immune system's role in disease risk.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

Researchers used genetic data to investigate whether seven different conditions, including Type 1 diabetes, causally affect the risk of cholangiocarcinoma (a cancer of the bile ducts).
The study found no evidence that genetic susceptibility to Type 1 diabetes increases cholangiocarcinoma risk.
The research highlights how the HLA region—an important part of the immune system—influences disease development, which is relevant to understanding Type 1 diabetes biology.
This type of study (called Mendelian randomization) helps scientists separate true causal relationships from simple associations.

What This Study Was Looking For

Cholangiocarcinoma is a rare but serious cancer that develops in the bile ducts. It occurs more frequently in East Asian populations, but scientists don't fully understand why some people are at higher genetic risk than others.

Researchers at BioBank Japan examined genetic data from thousands of people to test whether seven chronic conditions—chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, Type 1 diabetes, Type 2 diabetes, chronic gastritis, and chronic pancreatitis—might causally increase cholangiocarcinoma risk. In other words, they wanted to know which conditions genuinely influence cancer development, rather than just appearing related.

How the Immune System Connection Was Explored

The researchers focused on a specific region of our DNA called HLA (human leukocyte antigen), which is crucial for immune function. This region controls how our immune system recognizes and responds to threats. Understanding the HLA region is important for Type 1 diabetes research, since HLA genetics play a major role in Type 1 diabetes susceptibility.

By examining which genetic variations in the HLA region drove disease associations, the team could better understand the biological mechanisms—the 'why' behind disease links—rather than just seeing that connections existed.

Key Findings: What Did and Didn't Show a Link

The study found one significant causal relationship: genetic susceptibility to chronic hepatitis B was associated with a 24% higher likelihood of developing cholangiocarcinoma compared to people without that genetic susceptibility. This finding held up after rigorous statistical testing and sensitivity checks.

Importantly, Type 1 diabetes showed no significant causal effect on cholangiocarcinoma risk in this study. Neither did Type 2 diabetes, chronic hepatitis C, autoimmune hepatitis, chronic gastritis, or chronic pancreatitis. This means the genetic factors that predispose someone to Type 1 diabetes do not appear to increase cholangiocarcinoma risk.

What This Means for Type 1 Diabetes Understanding

While this study did not identify a direct link between Type 1 diabetes genetics and bile duct cancer, it reinforces something important: Type 1 diabetes and many other conditions are deeply connected to immune system genetics, particularly the HLA region. This is why researchers continue to study HLA variation as they work to understand Type 1 diabetes development and risk factors.

This type of genetic research—called Mendelian randomization—helps scientists untangle which associations are genuinely causal and which are coincidental. These methods are valuable tools for the Type 1 diabetes research community as investigators search for modifiable risk factors and new prevention strategies.

Evidence label

Source: Asian Pacific journal of cancer prevention : APJCP. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.